Fatigue News and Research

RSS

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

A high concentration of multi-strain probiotic helps to reduce mild to moderate episodes of chemotherapy-induced diarrhea in cancer patients, according to results of a phase II/III study in India.

22 Oct 2018

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus

A bioelectronic medicine device was effective in reducing pain and fatigue in patients with lupus, according to Feinstein Institute for Medical Research Professor Cynthia Aranow, MD, who will present pilot clinical trial results Tuesday at the American College of Rheumatology/Association of Rheumatology Professional's Annual Meeting.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.

22 Oct 2018

Physical activity lowers cardiovascular mortality risk in frail older adults

Frailty is a health condition that increases risks of poor health, falls, disability, and death in older adults. Signs of frailty include weakness, weight loss, slow walking speed, exhaustion, and low levels of activity.

19 Oct 2018

Patients once thought incurable can benefit from high-dose radiation therapy

In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live and doubles how long they live without cancer.

17 Oct 2018

New blood test could spare cancer patients from unnecessary chemotherapy

Cancer patients could be spared unnecessary chemotherapy - and its side effects - by a new blood test that is in clinical trials at more than 40 hospitals in Australia and New Zealand.

17 Oct 2018

Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant

Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders.

17 Oct 2018

HIV-infected infants more likely to acquire congenital cytomegalovirus infection

Infants born to HIV-positive mothers had high rates of congenital cytomegalovirus, or CMV. Infants who also were infected before birth by the virus that causes AIDS were especially prone to CMV infection.

16 Oct 2018

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the United States: BELVIQ, product name for once-daily formulation in the United States: BELVIQ XR, "lorcaserin") in 17 countries in Latin America and the Caribbean, excluding Brazil, to Eurofarma Laboratorios S.A. which has a business foundation in Latin America.

16 Oct 2018

New project aims to deliver fast, effective treatment for autoimmune rheumatic diseases

Affecting around 2 % of the population, autoimmune rheumatic diseases can have severe symptoms, including painful and swollen joints, fever, rashes, fatigue and sensitivity to the sun, with patients needing regular check-ups.

15 Oct 2018

Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism

A new "metal-coordinated" drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to results of a study published in the journal Thyroid this month.

15 Oct 2018

King's commemorates activities and research on World Arthritis Day

King's has a long history with arthritis research and been recognised as having one of the premier rheumatology research units in Europe.

12 Oct 2018

World Arthritis Day: New campaign raises awareness for early diagnosis of rheumatic diseases

The European League Against Rheumatism, EULAR, calls for people to come together on World Arthritis Day (12th October) to raise awareness of rheumatic and musculoskeletal diseases. EULAR's Don't Delay, Connect Today Campaign aims to improve early diagnosis and timely access to care to help benefit the lives of the 120 million people in Europe with RMDs.

12 Oct 2018

Study sheds light on lupus's autoimmune origins in precursor cells

In the autoimmune disease systemic lupus erythematosus or SLE, the immune system produces antibodies against parts of the body itself. How cells that produce those antibodies escape the normal "checks and balances" has been unclear, but recent research from Emory University School of Medicine sheds light on a missing link.

11 Oct 2018

Some cancer patients may benefit more from exercise than others

A new article in the Journal of the National Cancer Institute finds that some cancer patients appear to benefit more from exercise than others.

10 Oct 2018

$Thesis sheds new light on women with vertebral compression fractures$

Thesis sheds new light on women with vertebral compression fractures

Older women who suffer vertebral fractures rarely attract the attention of health care providers. A dissertation at Sahlgrenska Academy, Sweden, throws new light on a group of individuals with chronic pain as a constant companion.

9 Oct 2018

Fatigue News and Research

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

Physical activity lowers cardiovascular mortality risk in frail older adults

Patients once thought incurable can benefit from high-dose radiation therapy

New blood test could spare cancer patients from unnecessary chemotherapy

Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant

HIV-infected infants more likely to acquire congenital cytomegalovirus infection

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

New project aims to deliver fast, effective treatment for autoimmune rheumatic diseases

Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism

King's commemorates activities and research on World Arthritis Day

World Arthritis Day: New campaign raises awareness for early diagnosis of rheumatic diseases

Study sheds light on lupus's autoimmune origins in precursor cells

Some cancer patients may benefit more from exercise than others

Thesis sheds new light on women with vertebral compression fractures

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News